RXRX vs. BEAM

Last updated Jun 3, 2026

RXRX (Recursion Pharmaceuticals, Inc.) and BEAM (Beam Therapeutics Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 5 years, RXRX returned -33.81%/yr vs -18.35%/yr for BEAM. A 0.62 correlation means they provide meaningful diversification when combined.

Performance

RXRX vs. BEAM - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Recursion Pharmaceuticals, Inc. (RXRX) and Beam Therapeutics Inc. (BEAM). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, RXRX achieves a -11.74% return, which is significantly lower than BEAM's 4.47% return.

RXRX

• 1D: -4.75%
• 1M: 6.49%
• YTD: -11.74%
• 6M: -16.44%
• 1Y: -17.39%
• 3Y*: -24.02%
• 5Y*: -33.81%
• 10Y*: —

BEAM

• 1D: -7.00%
• 1M: -5.67%
• YTD: 4.47%
• 6M: 23.92%
• 1Y: 78.88%
• 3Y*: -5.24%
• 5Y*: -18.35%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

RXRX vs. BEAM - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021
RXRX Recursion Pharmaceuticals, Inc.	-11.74%	-39.50%	-31.44%	27.89%	-54.99%	-45.27%
BEAM Beam Therapeutics Inc.	4.47%	11.77%	-8.89%	-30.40%	-50.92%	9.63%

Correlation

The correlation between RXRX and BEAM is 0.57, which is moderate. They share some common price drivers but move independently often enough to provide real diversification benefit when combined.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.57
Correlation (3Y) Calculated over the trailing 3-year period	0.61
Correlation (5Y) Calculated over the trailing 5-year period	0.63
Correlation (All Time) Calculated using the full available price history since Apr 19, 2021	0.62

The correlation between RXRX and BEAM has been stable across timeframes, ranging from 0.57 to 0.63 - a consistent structural relationship.

Fundamentals

Market Cap RXRX : $1.91B BEAM : $2.99B
EPS RXRX : -$1.17 BEAM : -$0.63
PS Ratio RXRX : 26.15 BEAM : 22.59
PB Ratio RXRX : 1.86 BEAM : 2.57
Total Revenue (TTM) RXRX : $66.29M BEAM : $132.27M
Gross Profit (TTM) RXRX : -$22.83M BEAM : -$84.92M
EBITDA (TTM) RXRX : -$505.90M BEAM : -$68.39M

Return for Risk

RXRX vs. BEAM — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

RXRX

RXRX Risk / Return Rank: 32
RXRX Sharpe Ratio Rank: 31
RXRX Sortino Ratio Rank: 33
RXRX Omega Ratio Rank: 32
RXRX Calmar Ratio Rank: 32
RXRX Martin Ratio Rank: 33

BEAM

BEAM Risk / Return Rank: 73
BEAM Sharpe Ratio Rank: 73
BEAM Sortino Ratio Rank: 75
BEAM Omega Ratio Rank: 68
BEAM Calmar Ratio Rank: 75
BEAM Martin Ratio Rank: 74

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

RXRX vs. BEAM - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Recursion Pharmaceuticals, Inc. (RXRX) and Beam Therapeutics Inc. (BEAM). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	RXRX	BEAM	Difference
Sharpe ratio Return per unit of total volatility	-0.24	1.07	-1.31
Sortino ratio Return per unit of downside risk	0.16	2.02	-1.87
Omega ratio Gain probability vs. loss probability	1.02	1.22	-0.21
Calmar ratio Return relative to maximum drawdown	-0.23	2.17	-2.41
Martin ratio Return relative to average drawdown	-0.39	4.72	-5.11
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

RXRX vs. BEAM - Sharpe Ratio Comparison

The current RXRX Sharpe Ratio is -0.24, which is lower than the BEAM Sharpe Ratio of 1.07. The chart below compares the historical Sharpe Ratios of RXRX and BEAM, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	RXRX	BEAM	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.24	1.07	-1.31
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.36	-0.24	-0.12
Sharpe Ratio (All Time) Calculated using the full available price history	-0.37	0.09	-0.46

Drawdowns

RXRX vs. BEAM - Drawdown Comparison

The maximum RXRX drawdown since its inception was -93.13%, roughly equal to the maximum BEAM drawdown of -89.12%. Use the drawdown chart below to compare losses from any high point for RXRX and BEAM.

Drawdown Indicators

	RXRX	BEAM	Difference
Max Drawdown Largest peak-to-trough decline	-93.13%	-89.12%	-4.01%
Max Drawdown (1Y) Largest decline over 1 year	-58.17%	-38.15%	-20.02%
Max Drawdown (3Y) Largest decline over 3 years	-82.09%	-67.74%	-14.35%
Max Drawdown (5Y) Largest decline over 5 years	-93.13%	-89.12%	-4.01%
Current Drawdown Current decline from peak	-91.27%	-78.32%	-12.95%
Average Drawdown Average peak-to-trough decline	-75.33%	-59.80%	-15.53%
Ulcer Index Depth and duration of drawdowns from previous peaks	35.04%	17.57%	+17.47%

Volatility

RXRX vs. BEAM - Volatility Comparison

The current volatility for Recursion Pharmaceuticals, Inc. (RXRX) is 18.74%, while Beam Therapeutics Inc. (BEAM) has a volatility of 21.75%. This indicates that RXRX experiences smaller price fluctuations and is considered to be less risky than BEAM based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	RXRX	BEAM	Difference
Volatility (1M) Calculated over the trailing 1-month period	18.74%	21.75%	-3.01%
Volatility (6M) Calculated over the trailing 6-month period	44.79%	53.51%	-8.72%
Volatility (1Y) Calculated over the trailing 1-year period	73.46%	73.87%	-0.41%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	93.46%	75.70%	+17.76%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	93.62%	80.33%	+13.29%

Dividends

RXRX vs. BEAM - Dividend Comparison

Neither RXRX nor BEAM has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

Frequently Asked Questions

Can I hold both RXRX and BEAM in my portfolio?

RXRX and BEAM have a correlation of 0.57, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, RXRX or BEAM?

BEAM has higher volatility (21.75%) compared to RXRX (18.74%). In terms of maximum drawdown, RXRX dropped -93.13% vs BEAM's -89.12%.

Which has better risk-adjusted returns?

BEAM currently has the higher Sharpe Ratio (1.07 vs -0.24), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.